Latest Articles

Publication Date
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma - MedPage Today

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of CRT vs Chemotherapy for Locally Advanced Endometrial Carcinoma MedPage Today

Published: April 9, 2025, 3:15 p.m.
Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients - Nature.com

Establishment and validation of a prognostic nomogram for overall survival in type II endometrial carcinoma patients Nature.com

Published: March 6, 2025, 6:11 a.m.
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com

Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com

Published: March 5, 2025, 11:04 a.m.
Validation of Tumor Budding as a Prognostic Factor in Ovarian Clear Cell Carcinoma Using an Independent Cohort.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-related neoplasm, in which traditional histologic grading does not show prognostic significance. Tumor budding was associated with poorer outcomes in OCCC in previous …

Published: Jan. 10, 2025, midnight
The surgical, histopathological characteristics, and survival outcome of ovarian clear cell carcinoma: a retrospective case series sharing the experience of a tertiary cancer centre.

Ovarian clear cell carcinoma (OCCC) is a rare and distinct subtype of epithelial ovarian cancer (EOC). It is unique in several biological aspects. This study analyzes the clinicopathological features and …

Published: Sept. 11, 2024, midnight
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy - The ASCO Post

Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy The ASCO Post

Published: March 27, 2024, 6:45 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!